IMUNON to Present Phase 3 OVATION 3 Study of IMNN-001 in Advanced Ovarian Cancer at IGCS 2025 Annual Global Meeting

Trials-in-progress poster of ongoing pivotal Phase 3 trial of DNA-mediated immunotherapy accepted at both IGCS and ESMO Congress ...
Le Lézard

Altamira Therapeutics Announces Successful Nanoparticle-Based Delivery of DNA Molecules

Demonstrated feasibility of effective DNA delivery with Company's xPhore™ nanoparticle technologyDNA delivery technology to be offered as GenePhore™ to biotech / pharma companiesAddressing large and ...
eLife

Structure-based Design of Chimeric Influenza Hemagglutinins to Elicit Cross-group Immunity

This important study presents a thoughtful design and characterization of chimeric influenza hemagglutinin (HA) head domains combining elements of distinct receptor-binding sites. The results provide ...

Altamira Therapeutics Ltd.: Altamira Therapeutics Announces Successful Nanoparticle-Based Delivery of DNA Molecules

Demonstrated feasibility of effective DNA delivery with Company's xPhore nanoparticle technologyDNA delivery technology to be offered as GenePhore to biotech / pharma companiesAddressing large and gro ...
Le Lézard

Rigel Reports Third Quarter 2025 Financial Results and Provides Business Update

Rigel Pharmaceuticals, Inc. , a commercial stage biotechnology company focused on hematologic disorders and cancer, today reported financial results for the third quarter ended September 30, 2025, ...
eLife

Abnormal shear stress induces ferroptosis in endothelial cells via KLF6 downregulation

This study presents valuable findings on the role of KLF6 in in vitro endothelial cells exposed to altered (high or low) shear stress with a customized microfluidic device to investigate mechanisms of ...